Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.

Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.

What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.

The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.